Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Cell Signal. 2016 Jun 11;28(9):1364–1379. doi: 10.1016/j.cellsig.2016.06.012

Figure 1. Heme-independent activation of sGC by BAY60-2770.

Figure 1

Figure 1

(A) Rat primary arterial smooth muscle (ASM) cells were treated with the phosphodiesterase inhibitor IBMX (1 mM) for 15 minutes prior to co-incubation with/without the soluble guanylyl cyclase (sGC) inhibitor ODQ (10µM) containing vehicle (VEH), the heme-dependent sGC stimulator BAY41-2272 (BAY41; 1 µM), or the heme-independent sGC activator BAY60-2770 (BAY60; 1 µM), and cGMP content was analyzed after 15 minutes. Results show significant increases in cGMP content in BAY41 and BAY60 groups compared to VEH controls. ODQ significantly decreased the BAY41-mediated cGMP increase back to VEH control levels but significantly potentiated cGMP content in BAY60-treated cells. n = 4 wells per group. * = vs. appropriate VEH; # = vs. appropriate group without ODQ. (B) Rat primary ASM cells were incubated with VEH or BAY60 (0.001–10 µM) and cGMP content was analyzed after 15 minutes. Results show significant increases in cGMP content at 1 and 10 µM BAY60 compared to VEH controls. (C) Using VEH or BAY60 (1 µM), time course experiments were performed for cGMP content up through 120 min and results show maximum production of cGMP after 15 min BAY60 treatment with sustained elevation of cGMP through 120 min. n = 3 in duplicate per treatment group.